Myasthenia GravisMG-ExNCT06491238
Light vs. Moderate Intensity Exercise in Individuals With Myasthenia Gravis
A study testing Light Intensity Exercise and Moderate Intensity Exercise in people with Myasthenia Gravis, run by HealthPartners Institute at 1 site in United States.
Trial summary
The overall purpose of this pilot study is to examine the feasibility, acceptability, and tolerability of light and moderate intensity exercise in adults with MGeffect of light vs. moderate intensity exercise on health outcomes. Read more about this study
- Who is it for?
- Ages 18 to 80 years
- Conditions the study is for
- Myasthenia Gravis
- What is being tested?
- Light Intensity Exercise and Moderate Intensity Exercise
- Type of treatment
- Lifestyle or therapy programme
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 20 participants
- Where
- 1 siteUnited States
- Study dates
- 16 Sep 2024to Dec 2026
- Phase
- Interventional
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 to 80 years
- All sexes
- No healthy volunteers
- Adult, Older adult
Who may be able to join
- Ability to provide and provision of signed and dated informed consent form.
- Age 18-80
- Diagnosis of generalized MG.
- On a stable MG prescription medication regimen for the last 3 months.
Who cannot join
- Non-English speaking
- Regular exercise participation within the month prior to study enrollment or any outside exercise participation during the study intervention period.
- Significant cognitive impairment of any etiology that would impact study participation.
- History of heart failure, chronic lung disease, angina or any other condition that causes unreasonable shortness of breath on exertion.
- History of any serious neurological, psychiatric, or substance use disorders that would impact study participation.
- Women who are currently pregnant or planning to become pregnant during the study.
Show all 9Show fewer
- Any other medical conditions that could affect their ability to participate in exercise for the study duration (as determined by study investigators).
- Active participation or past participation ≤3 months in any other interventional research study.
- Unwilling to participate in all study related activities.
Trial locations and contacts
1 site in 1 country. Contact the study team or a site near you to ask about taking part.
United States1 site, 1 recruiting
- Recruiting
HealthPartners Neuroscience Center
Saint Paul, Minnesota, 55130
Clinical Trial Coordinator, 651-495-6363, ClincialTrials@HealthPartners.com
About this study
The overall purpose of this pilot study is to examine the feasibility, acceptability, and tolerability of light and moderate intensity exercise in adults with MGeffect of light vs. moderate intensity exercise on health outcomes. Participants will be enrolled into the NeuroWell exercise program, which is geared toward individuals with neurological disorders or injuries and led by Certified Exercise Physiologists (CEPs) at the HealthPartners Neuroscience Center. A total of 20 people with MG will be enrolled in this study and participate in a small group exercise program 3 times a week for 12 weeks. Participants will be randomized into two exercise groups: 1) Light intensity or 2) Moderate intensity. We hypothesize that light and moderate intensity exercise will be feasible, acceptable, and tolerable in adults with MG and that individuals in the light intensity exercise group will be able to achieve the same improvement in health outcomes as the moderate intensity group.
- Conditions
- Myasthenia Gravis
- Being tested
- Light Intensity Exercise, Moderate Intensity Exercise
- Medical subject headings
- Myasthenia Gravis
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Light Intensity ExerciseBehavioural
12 weeks light intensity strength and endurance NeuroWell exercise program, specifically developed for individuals with neurological disorders or injuries. Participants have the intensity goals descripted in the experimental arm.
Moderate Intensity ExerciseBehavioural
12 weeks moderate intensity strength and endurance NeuroWell exercise program, specifically developed for individuals with neurological disorders or injuries. Participants have the intensity goals descripted in the experimental arm.
| Study group | Role | What they receive |
|---|---|---|
| Light intensity Exercise | Experimental | Aerobic intensity levels: Heart rate reserve (HRR) 30-39%, 9-11 Borg Rate of Perceived Exertion (RPE) Strength intensity levels: %One Repetition Max (1RM) 40-50%, OMNI RPE 1-4 Receives: Behavioral: Light Intensity Exercise |
| Moderate intensity Exercise | Experimental | Aerobic intensity levels: HRR 40-59%, 12-13 Borg RPE Strength intensity levels: %1RM 60-80%, OMNI RPE 5-6 Receives: Behavioral: Moderate Intensity Exercise |
What is being measured
The primary outcome is the main question the study is designed to answer.
Feasibility of light and moderate intensity exercise
Percent of participants recruited of potential participants contacted. Range: [0-100]. Higher percentage indicates higher feasibility
Measured: 12 weeks
Acceptability of light and moderate intensity exercise
Percent of participants who complete the program of participants who start the program. Range: [0-100]. Higher percentage indicates higher acceptability
Measured: 12 weeks
Tolerability of light and moderate intensity exercise
Percent of classes participants complete during the course of the program. Range: [0-100]. Higher percentage indicates higher tolerability.
Measured: 12 weeks
Secondary outcomes (4)
Cardiovascular Test - 6-minute walk test
Pre-post change in distance a person can walk during the 6-minute walk test. Change = Post distance - pre distance. Larger positive difference in distance indicates a larger improvement in cardiovascular health from pre-post program.
Measured: 12 weeks
Cardiovascular and Strength test
Pre-post change in time it takes a person to transfer from seated to standing position and then back to seated position 5 times. Change = Post time- pre time. Larger positive difference in time indicates a larger improvement in cardiovascular health and strength from pre-post program.
Measured: 12 weeks
Strength Test - 1-RM Upper Limb
Pre-post change in weight that can be lifted during the 1-RM test. Change = Post 1-RM upper limb weight -pre 1-RM upper limb weight. Larger positive difference in weight lifted indicates a larger improvement in upper limb strength from pre-post program.
Measured: 12 weeks
Strength Test - 1-RM Lower Limb
Pre-post change in weight that can be lifted during the 1-RM test. Change = Post 1-RM lower limb weight -pre 1-RM lower limb weight. Larger positive difference in weight lifted indicates a larger improvement in lower limb strength from pre-post program.
Measured: 12 weeks
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted9 Jul 2024
- Study start16 Sep 2024
- Primary completionDec 2026 (estimated)
- Study completionDec 2026 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Myasthenia GravisStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- None (open label)
- Enrolment
- 20 participants (estimated)
Sponsor and investigators
- Lead sponsor
- HealthPartners Institute
- Sponsor type
- University, hospital or other
- Responsible party
- Sponsor
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT06491238
- Sponsor's protocol ID
- A24-169
- Acronym
- MG-Ex
- Status last verified
- Mar 2026
- First submitted
- 21 Jun 2024
- Last updated
- 23 Mar 2026
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- Undecided
Study at a glance
From the registry record, last updated by the sponsor on 23 Mar 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Light vs. Moderate Intensity Exercise in Individuals With Myasthenia Gravis
- ClinicalTrials.gov ID
- NCT06491238
- Acronym / sponsor ID
- MG-Ex / A24-169
- Conditions
- Myasthenia Gravis
- Study type
- Interventional
- Recruitment status
- Recruiting
- Enrolment
- 20 participants (estimated)
- Lead sponsor
- HealthPartners InstituteUniversity, hospital or other
- Study start
- 16 Sep 2024 (actual)
- Primary completion
- Dec 2026 (estimated)
- Study completion
- Dec 2026 (estimated)
- First posted
- 9 Jul 2024 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
The overall purpose of this pilot study is to examine the feasibility, acceptability, and tolerability of light and moderate intensity exercise in adults with MGeffect of light vs. moderate intensity exercise on health outcomes. Participants will be enrolled into the NeuroWell exercise program, which is geared toward individuals with neurological disorders or injuries and led by Certified Exercise Physiologists (CEPs) at the HealthPartners Neuroscience Center. A total of 20 people with MG will be enrolled in this study and participate in a small group exercise program 3 times a week for 12 weeks. Participants will be randomized into two exercise groups: 1) Light intensity or 2) Moderate intensity. We hypothesize that light and moderate intensity exercise will be feasible, acceptable, and tolerable in adults with MG and that individuals in the light intensity exercise group will be able to achieve the same improvement in health outcomes as the moderate intensity group.
Study design
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- None (open label)
- Number of arms
- 2
| Arm | Type | Receives |
|---|---|---|
| Light intensity Exercise | Experimental | Behavioral: Light Intensity ExerciseAerobic intensity levels: Heart rate reserve (HRR) 30-39%, 9-11 Borg Rate of Perceived Exertion (RPE) Strength intensity levels: %One Repetition Max (1RM) 40-50%, OMNI RPE 1-4 |
| Moderate intensity Exercise | Experimental | Behavioral: Moderate Intensity ExerciseAerobic intensity levels: HRR 40-59%, 12-13 Borg RPE Strength intensity levels: %1RM 60-80%, OMNI RPE 5-6 |
Who may qualify
- Ages
- 18 to 80 years
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (4 listed)
- Ability to provide and provision of signed and dated informed consent form.
- Age 18-80
- Diagnosis of generalized MG.
- On a stable MG prescription medication regimen for the last 3 months.
Key exclusion criteria (9 listed)
- Non-English speaking
- Regular exercise participation within the month prior to study enrollment or any outside exercise participation during the study intervention period.
- Significant cognitive impairment of any etiology that would impact study participation.
- History of heart failure, chronic lung disease, angina or any other condition that causes unreasonable shortness of breath on exertion.
- History of any serious neurological, psychiatric, or substance use disorders that would impact study participation.
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Light Intensity Exercise12 weeks light intensity strength and endurance NeuroWell exercise program, specifically developed for individuals with neurological disorders or injuries. Participants have the intensity goals descripted in the experimental arm. | Behavioural | Light intensity Exercise |
| Moderate Intensity Exercise12 weeks moderate intensity strength and endurance NeuroWell exercise program, specifically developed for individuals with neurological disorders or injuries. Participants have the intensity goals descripted in the experimental arm. | Behavioural | Moderate intensity Exercise |
Primary outcome
Feasibility of light and moderate intensity exercise
Time frame: 12 weeks
Percent of participants recruited of potential participants contacted. Range: [0-100]. Higher percentage indicates higher feasibility
Acceptability of light and moderate intensity exercise
Time frame: 12 weeks
Percent of participants who complete the program of participants who start the program. Range: [0-100]. Higher percentage indicates higher acceptability
Tolerability of light and moderate intensity exercise
Time frame: 12 weeks
Percent of classes participants complete during the course of the program. Range: [0-100]. Higher percentage indicates higher tolerability.
4 secondary outcomes
Cardiovascular Test - 6-minute walk test
Time frame: 12 weeks
Cardiovascular and Strength test
Time frame: 12 weeks
Strength Test - 1-RM Upper Limb
Time frame: 12 weeks
Strength Test - 1-RM Lower Limb
Time frame: 12 weeks
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 23 Mar 2026.
- Individual participant dataSharing planned: Undecided
Related trials for Myasthenia Gravis
Active, not recruitingPhase 3
An Extension Study Evaluating 6-week Treatment Cycles of Rozanolixizumab in Pediatric Study Participants With Generalized Myasthenia Gravis
Generalized Myasthenia Gravis
RecruitingPhase 3
A Study to Evaluate the Efficacy and Safety of Rozanolixizumab in Adult Participants With Ocular Myasthenia Gravis
Ocular Myasthenia Gravis
Active, not recruiting
Effects of Whole-body Electrical Muscle Stimulation Exercise on Adults With Neuromuscular Disease
Neuromuscular Diseases (NMD), Amyotrophic Lateral Sclerosis
RecruitingPhase 3
A Study to Evaluate The Long-Term Safety And Efficacy of Rozanolixizumab in Adult Participants With Ocular Myasthenia Gravis
Ocular Myasthenia Gravis
Recruiting
Holistic Assessment and Remote Digital MONitoring of mYasthenia Gravis Via MyoSense 360
Myasthenia Gravis, Generalized
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing Light Intensity Exercise and Moderate Intensity Exercise in people with Myasthenia Gravis, run by HealthPartners Institute at 1 site in United States.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 4 inclusion and 9 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: looking for participants now, as of the sponsor's last update on 23 Mar 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in United States. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
Contact Clinical Trials Coordinator (651-495-6363, ClinicalTrials@HealthPartners.com), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Feasibility of light and moderate intensity exercise (time frame: 12 weeks). The study lists 3 primary outcomes in all. It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 23 Mar 2026.